Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rettig

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
JAMA Network Open|December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysisTing Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
JAMA Oncology|November 20, 2025
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active SurveillanceMatthew R Cooperberg, John R Bihn, John M Culnan, et al.
JAMA Network Open|April 19, 2022
Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical TrialNicholas G Nickols, Zhibao Mi, Ellen DeMatt, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patientsRebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized TrialsTing Martin Ma, Yilun Sun, Shawn Malone, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
JAMA Network Open|December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysisTing Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
JAMA Oncology|November 20, 2025
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active SurveillanceMatthew R Cooperberg, John R Bihn, John M Culnan, et al.
JAMA Network Open|April 19, 2022
Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical TrialNicholas G Nickols, Zhibao Mi, Ellen DeMatt, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patientsRebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized TrialsTing Martin Ma, Yilun Sun, Shawn Malone, et al.
Pageof 15